Armènia - anglès - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

accord healthcare limited - betahistine (betahistine dihydrochloride) - tablets - 8mg

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - betahistine dihydrochloride, quantity: 16 mg - tablet - excipient ingredients: colloidal anhydrous silica; microcrystalline cellulose; povidone; lactose monohydrate; stearic acid; crospovidone - meniere?s syndrome as defined by the following core symptoms: ,- vertigo (with nausea/vomiting) ,- hearing loss (hardness of hearing) ,- tinnitus

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - betahistine dihydrochloride, quantity: 16 mg - tablet - excipient ingredients: microcrystalline cellulose; colloidal anhydrous silica; stearic acid; lactose monohydrate; povidone; crospovidone - meniere?s syndrome as defined by the following core symptoms: ,- vertigo (with nausea/vomiting) ,- hearing loss (hardness of hearing) ,- tinnitus

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - betahistine dihydrochloride, quantity: 16 mg - tablet - excipient ingredients: povidone; lactose monohydrate; crospovidone; colloidal anhydrous silica; stearic acid; microcrystalline cellulose - meniere?s syndrome as defined by the following core symptoms: ,- vertigo (with nausea/vomiting) ,- hearing loss (hardness of hearing) ,- tinnitus

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - betahistine dihydrochloride, quantity: 16 mg - tablet - excipient ingredients: povidone; colloidal anhydrous silica; crospovidone; lactose monohydrate; microcrystalline cellulose; stearic acid - meniere?s syndrome as defined by the following core symptoms: ,- vertigo (with nausea/vomiting) ,- hearing loss (hardness of hearing) ,- tinnitus

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - betahistine dihydrochloride, quantity: 16 mg - tablet, uncoated - excipient ingredients: mannitol; microcrystalline cellulose; purified talc; citric acid; colloidal anhydrous silica - meniere's syndrome as defined by the following core symptoms: vertigo (with nausea/vomiting), hearing loss (hardness of hearing) and tinnitus.

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - betahistine dihydrochloride, quantity: 16 mg - tablet, uncoated - excipient ingredients: purified talc; mannitol; microcrystalline cellulose; citric acid; colloidal anhydrous silica - meniere's syndrome as defined by the following core symptoms: vertigo (with nausea/vomiting), hearing loss (hardness of hearing) and tinnitus.

Nova Zelanda - anglès - Medsafe (Medicines Safety Authority)

viatris limited - betahistine dihydrochloride 16mg;   - tablet - 16 mg - active: betahistine dihydrochloride 16mg   excipient: citric acid monohydrate colloidal silicon dioxide mannitol microcrystalline cellulose purified talc purified water - m?ni?re's syndrome as defined by the following core symptoms: · vertigo (with nausea/vomiting) · hearing loss (hardness of hearing) · tinnitus

Regne Unit - anglès - MHRA (Medicines & Healthcare Products Regulatory Agency)

flamingo pharma (uk) ltd - betahistine dihydrochloride - oral tablet - 8mg

Malta - anglès - Medicines Authority

aurobindo pharma (malta) limited vault 14, level 2, valletta waterfront, floriana frn 1913, malta - betahistine dihydrochloride - tablet - betahistine dihydrochloride 16 mg - other nervous system drugs